Skip to main content

Table 1 Baseline patient demographics and MMSE scores (ITT set)

From: Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy

 

MOD-SEV subgroupa

MOD subgroupb

Characteristic

Memantine added to donepezil

( n = 264)

Placebo added to donepezil

( n = 246)

Memantine added to donepezil

( n = 186)

Placebo added to donepezil

( n = 181)

Female

155 (58.7)

151 (61.4)

114 (61.3)

110 (60.8)

Age, mean (SD) years

75.1 (8.5)

75.8 (8.5)

75.9 (8.4)

76.4 (8.2)

Caucasian

236 (89.4)

230 (93.5)

166 (89.2)

171 (94.5)

Black

10 (3.8)

6 (2.4)

5 (2.7)

4 (2.2)

Asian

3 (1.1)

1 (0.4)

3 (1.6)

1 (0.6)

Other

15 (5.7)

9 (3.7)

12 (6.5)

5 (2.8)

MMSE score, mean (SD)

11.9 (3.9)

11.7 (3.7)

13.9 (2.5)

13.4 (2.6)

  1. Data are number (%) unless otherwise specified. aModerate to severe Alzheimer's disease (AD) (MMSE 5 to 19 at baseline), receiving donepezil (10 mg/day). bModerate AD (MMSE 10 to 19 at baseline), receiving donepezil (10 mg/day). MMSE, Mini-Mental State Examination; ITT, intention-to-treat.